Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1189 results
June 2018
-
Ad-hoc Release
Novartis completes sale of stake in consumer healthcare joint venture to GSK for USD13.0 billion
Basel, June 1, 2018 - Novartis AG ("Novartis") today announced the completion of the divestment to GlaxoSmithKline PLC ("GSK") of its 36.5 percent stake in a consumer healthcare joint venture (JV)… -
Press Release
Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab
Sandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatology Positive CHMP opinion… -
Ad-hoc Release
Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine
If approved, Aimovig®(erenumab) is expected to be the first and only available therapy designed specifically for migraine prevention in the EU Positive opinion based on robust data package…
May 2018
-
Press Release
FDA expedites review of Novartis drug Promacta® for first-line severe aplastic anemia (SAA)
Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy (… -
Press Release
Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto®
Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12)[1]… -
Press Release
Sandoz receives European Commission approval for Zessly® (infliximab) in gastroenterological, rheumatological and dermatological diseases
European Commission's (EC) approval based on comprehensive data package confirming that Zessly® matches safety, efficacy and quality of reference medicine Biosimilars such as Zessly enable… -
Ad-hoc Release
Novartis and Amgen announce FDA approval of Aimovig(TM) (erenumab), a novel treatment developed specifically for migraine prevention
Migraine is a severe neurologic disease that profoundly impacts millions of patients in the United States Aimovig is the first and only FDA-approved treatment to block the calcitonin gene-… -
Press Release
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
Results from the Kisqali® MONALEESA clinical trial program, the largest industry- sponsored Phase III registration program researching a CDK4/6 inhibitor in HR+/HER2- advanced breast cancer, will… -
Press Release
Novartis kündigt Veränderungen in der Geschäftsleitung an
Felix R. Ehrat, Group General Counsel, tritt per 1. Juni 2018 zurück Shannon Thyme Klinger zum Group General Counsel ernannt Robert Weltevreden zum Leiter Novartis Business Services ernannt… -
Press Release
At the Meet Novartis Management investor event, Novartis highlights strategy to focus the company and drive sustainable growth
Full pipeline of late stage assets with blockbuster potential Positioned to deliver sales growth and margin expansion through 2022 Pipeline depth in key therapeutic areas and building new,… -
Press Release
Novartis announces changes to the Executive Committee
Felix R. Ehrat, Group General Counsel, will retire on June 1, 2018 Shannon Thyme Klinger appointed to Group General Counsel Robert Weltevreden appointed Head of Novartis Business Services… -
Press Release
Novartis successfully completes acquisition of AveXis, Inc.
The digital press release with multimedia content can be accessed here: Basel, May 15, 2018 - Novartis AG (NYSE: NVS) ("Novartis") today announced that it has completed the acquisition of…